SAP-001 is Shanton's lead investigational compound with First- and Best-in-Class potential in uncontrolled gout ...

SAP-001 is Shanton's lead investigational compound with First- and Best-in-Class potential in uncontrolled gout SINGAPORE and PRINCETON, N.J., May 19, 2025 /PRNewswire/ -- Shanton Pharma ...

Proceeds will be used to advance XORTX’s programs for gout •CALGARY, Alberta, May 19, 2025 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. ("XORTX" or the “Company”) (NASDAQ: XRTX | TSXV: XRTX | Frankfurt ...

The patent covers compositions and methods of formulating using XORTX’s proprietary formulations of xanthine oxidase inhibitors (“XOI”) for the treatment of health consequences of ...

Summary. Febuxostat is a novel non-purine selective inhibitor of xanthine oxidase for the management of hyperuricemia in patients with gout. The ability of febuxostat to decrease serum uric acid ...

Allopurinol (4-hydroxypyrazolo-(3, 4-d) pyrimidine, HPP), a xanthine oxidase inhibitor, offers a new concept in the prevention of the complications of hyperuricemia. By effectively blocking the ...

selective serotonin reuptake inhibitors (SSRIS), and xanthine oxidase inhibitors. Its products include Guaifenesin, Methocarbamol, Fexofenadine Hcl, Phenazopyridine Hcl, Fluconazole, Melitracen ...

Further, the company develops IBI128, a late-stage novel non-purine xanthine oxidase inhibitor; and IBI311, a recombinant anti-IGF-1R monoclonal antibody. Additionally, it distributes ...

XORTX is working to advance products that target aberrant purine metabolism and xanthine oxidase to decrease or inhibit production of uric acid. At XORTX, we are dedicated to developing medications ...

Serum concentrations of uric acid (UA), creatinine (Cr), urea nitrogen (UN), and xanthine oxidase (XOD) were quantified using commercial assay kits, following the manufacturer’s instructions (Nanjing ...